Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells1
暂无分享,去创建一个
J. Frelinger | W. Heath | A. Nowak | B. Robinson | R. Lake | B. Scott | E. Collins | A. Marzo | B. Robinson
[1] R. Zinkernagel. On cross‐priming of MHC class I‐specific CTL: rule or exception? , 2002, European journal of immunology.
[2] T. Witham,et al. 7-Hydroxystaurosporine-induced Apoptosis in 9L Glioma Cells Provides an Effective Antigen Source for Dendritic Cells and Yields a Potent Vaccine Strategy in an Intracranial Glioma Model , 2002, Neurosurgery.
[3] K. Murphy,et al. Lymphocyte activation and effector functions. , 2002, Current Opinion in Immunology.
[4] A. Nowak,et al. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. , 2002, Cancer research.
[5] G. Makin. Targeting apoptosis in cancer chemotherapy , 2002, Expert opinion on therapeutic targets.
[6] N. Glaichenhaus,et al. Tolerance to islet antigens and prevention from diabetes induced by limited apoptosis of pancreatic beta cells. , 2002, Immunity.
[7] P. Gibbs,et al. A phase II study of neoadjuvant biochemotherapy for stage III melanoma , 2002, Cancer.
[8] Y. Imai,et al. Combined intraarterial 5‐fluorouracil and subcutaneous interferon‐α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches , 2002, Cancer.
[9] J. Dunn,et al. Prospective Randomized Comparison of Dacarbazine (DTIC) Versus DTIC Plus Interferon-Alpha (IFN-α) in Metastatic Melanoma , 2001 .
[10] J. Mulé,et al. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. , 2001, Cancer research.
[11] W. Heath,et al. Cross-presentation in viral immunity and self-tolerance , 2001, Nature Reviews Immunology.
[12] V. Fadok,et al. Phagocyte receptors for apoptotic cells: recognition, uptake, and consequences. , 2001, The Journal of clinical investigation.
[13] K. Omoteyama,et al. Apoptosis and anticancer drug resistance. , 2001, Human cell.
[14] N. Bhardwaj,et al. Dendritic Cell–Dead Cell Interactions: Implications and Relevance for Immunotherapy , 2001, Journal of immunotherapy.
[15] V. Fadok,et al. Differential Effects of Apoptotic Versus Lysed Cells on Macrophage Production of Cytokines: Role of Proteases1 , 2001, The Journal of Immunology.
[16] S. Mukherjee,et al. Tumor Progression Despite Efficient Tumor Antigen Cross-Presentation and Effective “Arming” of Tumor Antigen-Specific CTL1 , 2001, The Journal of Immunology.
[17] M. Bevan,et al. Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo , 2000, The Journal of experimental medicine.
[18] B. Robinson,et al. Tumor-Specific CD4+ T Cells Have a Major “Post-Licensing” Role in CTL Mediated Anti-Tumor Immunity1 , 2000, The Journal of Immunology.
[19] I. Rennie,et al. Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells. , 2000, Cancer research.
[20] T. Ohtsuboa,et al. Enhancement of heat-induced heat shock protein (hsp)72 accumulation by doxorubicin (Dox) in vitro. , 2000, Cancer letters.
[21] N. Restifo. Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. , 2000, Current opinion in immunology.
[22] M. Lotze,et al. The dendritic cell and human cancer vaccines. , 2000, Current opinion in immunology.
[23] T. Whiteside,et al. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. , 2000, Cancer research.
[24] A. Buzaid. Strategies for combining chemotherapy and biotherapy in melanoma. , 2000, Cancer control : journal of the Moffitt Cancer Center.
[25] B. Lieubeau,et al. Role of Antigen-Presenting Cells in Long-Term Antitumor Response Based on Tumor-Derived Apoptotic Body Vaccination , 2000, Pathobiology.
[26] F. Huang,et al. A Discrete Subpopulation of Dendritic Cells Transports Apoptotic Intestinal Epithelial Cells to T Cell Areas of Mesenteric Lymph Nodes , 2000, The Journal of experimental medicine.
[27] R. Steinman,et al. The Induction of Tolerance by Dendritic Cells That Have Captured Apoptotic Cells , 2000, The Journal of experimental medicine.
[28] B. Krammer,et al. Cutting edge: differential effect of apoptotic versus necrotic tumor cells on macrophage antitumor activities. , 1999, Journal of immunology.
[29] P. Ricciardi-Castagnoli,et al. Delayed clearance of apoptotic lymphoma cells allows cross‐presentation of intracellular antigens by mature dendritic cells , 1999, Journal of leukocyte biology.
[30] L. Sherman,et al. Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens. , 1999, Journal of immunology.
[31] D. Lo,et al. Tumor antigens are constitutively presented in the draining lymph nodes. , 1999, Journal of immunology.
[32] H. Pircher,et al. Intrathymic deletion of MHC class I‐restricted cytotoxic T cell precursors by constitutive cross‐presentation of exogenous antigen , 1999, European journal of immunology.
[33] B. Robinson,et al. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. , 1999, Cancer research.
[34] Loise M. Francisco,et al. Immature Dendritic Cells Phagocytose Apoptotic Cells via αvβ5 and CD36, and Cross-present Antigens to Cytotoxic T Lymphocytes , 1998, The Journal of experimental medicine.
[35] M. Albert,et al. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs , 1998, Nature.
[36] D. Pardoll,et al. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[37] C. Kurts,et al. Class I–restricted Cross-Presentation of Exogenous Self-Antigens Leads to Deletion of Autoreactive CD8+ T Cells , 1997, The Journal of experimental medicine.
[38] H. Mcdevitt,et al. CD8(+) T cell-mediated spontaneous diabetes in neonatal mice. , 1996, Journal of immunology.
[39] G. Peters,et al. Schedule-dependent antitumor effect of gemcitabine in in vivo model system. , 1995, Seminars in oncology.
[40] D. Recine,et al. Carboplatin/etoposide/radiation plus escalating doses of paclitaxel in stage III non-small cell lung cancer: a preliminary report. , 1995, Seminars in oncology.
[41] C. Potten,et al. Apoptosis and cancer chemotherapy. , 1994, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[42] A. B. Lyons,et al. Determination of lymphocyte division by flow cytometry. , 1994, Journal of immunological methods.
[43] H. Mcdevitt,et al. A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity. , 1994, Immunity.
[44] D. Whitaker,et al. Establishment of a murine model of malignant mesothelioma , 1992, International journal of cancer.
[45] P. Srivastava,et al. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. , 2002, Annual review of immunology.
[46] A. Eggermont,et al. Pegylated liposomal tumor necrosis factor‐α results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil®) in soft tissue sarcoma‐bearing rats , 2002, International journal of cancer.
[47] M. Gottesman. Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.
[48] W. Heath,et al. Cross-presentation, dendritic cells, tolerance and immunity. , 2001, Annual review of immunology.
[49] L. Cartee,et al. Gemcitabine induces programmed cell death and activates protein kinase C in BG-1 human ovarian cancer cells , 1998, Cancer Chemotherapy and Pharmacology.
[50] P. Matzinger. Tolerance, danger, and the extended family. , 1994, Annual review of immunology.
[51] D. Berd. Low doses of chemotherapy to inhibit suppressor T cells. , 1989, Progress in clinical and biological research.